Clinical Trials List
Protocol Number213348 (4020-01-001)
NCT Number(ClinicalTrials.gov Identfier)NCT02817633
Completed
2016-02-24 - 2030-09-30
Phase I
Recruiting5
ICD-10C7A.1
Malignant poorly differentiated neuroendocrine tumors
ICD-10C7A.8
Other malignant neuroendocrine tumors
ICD-10C7B.09
Secondary carcinoid tumors of other sites
ICD-10C7B.1
Secondary Merkel cell carcinoma
ICD-10C7B.8
Other secondary neuroendocrine tumors
ICD-10C80.0
Disseminated malignant neoplasm, unspecified
ICD-10D3A.8
Other benign neuroendocrine tumors
ICD-10Z51.12
Encounter for antineoplastic immunotherapy
ICD-9199.0
Disseminated malignant neoplasm
A Phase 1 Dose Escalation and Cohort Expansion Study of TSR-022, an Anti-TIM-3 Monoclonal Antibody, in Patients With Advanced Solid Tumors (AMBER)
-
Trial Applicant
Pharmaceutical Research Associates Taiwan Inc.
-
Sponsor
-
Trial scale
Multi-Regional Multi-Center
-
Update
2026/06/03
Investigators and Locations
Co-Principal Investigator
- YU-HSUAN SHIH Division of Hematology & Oncology
- HSIN-CHEN LIN Division of Hematology & Oncology
- 黃儀倢 Digestive System Department
- SHAO-CIAO LUO Division of General Surgery
- YI-JU CHEN Division of General Surgery
- 吳峯旭 Division of General Surgery
- CHUNG-HSIN CHANG Digestive System Department
- 蔡炘儒 Digestive System Department
- 蘇德晟 Division of Radiology
- TENG-YU LEE Digestive System Department
- 陳家昌 Digestive System Department
The Actual Total Number of Participants Enrolled
0 Recruiting
Co-Principal Investigator
- 高婉真 Division of Hematology & Oncology
- 陳彥勳 Division of Hematology & Oncology
- 林正耀 Division of Hematology & Oncology
- Shang-Wen Chen Division of Hematology & Oncology
- 黃文聰 Division of Hematology & Oncology
- 陳昭勳 Division of Hematology & Oncology
- 林建良 Division of Hematology & Oncology
- 陳冠宇 Division of Hematology & Oncology
- 蕭聖諺 Division of Hematology & Oncology
The Actual Total Number of Participants Enrolled
0 Recruiting
Co-Principal Investigator
- 王瑜肇 Division of Gastroenterological Surgery
- 李兆偉 Division of General Surgery
- 林伯庭 Digestive System Department
- 滕威 Digestive System Department
- 吳庭榕 Division of Gastroenterological Surgery
- Wei-Chen Lee Division of General Surgery
- 洪豪謙 Division of General Surgery
- Chia-Hsun Hsieh Division of Hematology & Oncology
- 吳宗翰 Division of Gastroenterological Surgery
- 李勁樵 Division of General Surgery
- 鄭志軒 Division of General Surgery
- 呂嘉偉 Division of Radiology
- 周宏學 Division of Obstetrics & Gynecology
- Kun-Ming Chan Division of General Surgery
- Yi-Chung Hsieh Digestive System Department
The Actual Total Number of Participants Enrolled
0 Recruiting
Co-Principal Investigator
- I-Cheng Lee Digestive System Department
- Yi-Ping Hung Division of Hematology & Oncology
- Chien-An Liu Division of Radiology
- 齊振達 Digestive System Department
- San-Chi Chen Division of Hematology & Oncology
The Actual Total Number of Participants Enrolled
0 Recruiting
Principal Investigator
Chia-Jui Yen
Co-Principal Investigator
- Chih-Chieh Yen Division of Hematology & Oncology
- 劉奕廷 Division of Hematology & Oncology
The Actual Total Number of Participants Enrolled
0 Recruiting
Condition/Disease
Neoplasms
Objectives
Primary Objectives:
Parts 1e and 2:
To evaluate the antitumor activity of TSR-022 as monotherapy and/or in combination with TSR-042 or docetaxel in participants with solid tumors, using the objective response rate (ORR) assessed by the trial principal investigator using the Responsive Criteria for Response in Solid Tumors (RECIST) version 1.1.
To confirm the RP2D and dosing schedule for TSR-022 monotherapy.
To confirm the RP2D and dosing schedule for TSR-022 in combination with TSR-042.
Secondary Objectives:
To describe the pharmacokinetic (PK) profile of TSR-022 during monotherapy (Parts 1 and 2), and in combination with nivolumab (Part 1b), TSR-042 (Parts 1c, 1d, 1e, 1f, 1g, 1h, and Parts 2A, 2B, 2C, 2D), TSR-033 (Part 1d), and chemotherapy agents (Parts 1f, 1g, and 1h).
To evaluate the immunogenicity of TSR-022 as monotherapy, and in combination with TSR-042 (Parts 1c, 1e, 2A, 2B, 2C, 2D) and TSR-033. Part 2F: Assess the safety and tolerability of cobolimab + dostarlimab for HCC (e.g., the incidence of treatment-interventional adverse events (TEAEs), serious adverse events (SAEs), immune-mediated adverse events (imAEs), TEAEs leading to death, and AEs leading to discontinuation occurring during treatment or up to 90 days after the last dose of trial treatment).
Other endpoints for assessing clinical benefit include:
* ORR according to RECIST version 1.1 (Part 1 participants).
* ORR according to immune-related RECIST (irRECIST) (Part 2A, 2B, 2C, and 2D participants).
* Duration of response (DOR) according to RECIST version 1.1 (Part 2 participants).
* Duration of response (DOR) according to irRECIST (Part 2A, 2B, 2C, and 2D participants). • Disease control rate (DCR) according to RECIST version 1.1 (participants in Parts 1 and 2) and according to irRECIST (participants in Parts 2A, 2B, 2C, and 2D).
• Progression-free survival (PFS) according to RECIST version 1.1 (participants in Part 2) and according to irRECIST (participants in Parts 2A, 2B, 2C, and 2D).
• Overall survival (OS) (participants in Part 2).
• Alpha-fetoprotein (AFP) response (participants in Part 2F).
Test Drug
Intravenous infusion fluids
Active Ingredient
Cobolimab
Dostarlimab
Dostarlimab
Dosage Form
246
246
246
Dosage
MG
Endpoints
Safety:
• DLT
• Within the first 28 days (for patients receiving 2 doses of TSR 022 in Part 1a [i.e., days 1 and 15]), and
• Within the first 42 days (for patients receiving 3 doses of TSR 022 in Part 1b, and 3 doses of nivolumab in Part 1b [i.e., days 1, 15, and 29 of the first 42 days of treatment]), and
• Within the first 42 days (for patients receiving 2 doses each of TSR-022 and TSR-042 in Part 1c [i.e., days 1 and 21 of the first 42 days of treatment in Part 1])
• Within the first 42 days (for patients receiving 2 doses each of TSR-022, TSR-042, and TSR-033 in Part 1d [i.e., days 1 and 29 of the first 42 days of treatment]) [Part 1: Days 1 and 21 of the initial 42-day treatment period]
• During the initial 21 days (for patients receiving one dose each of TSR 022, TSR-042, and docetaxel in Part 1f).
• During the initial 21 days (for patients receiving one dose each of TSR 022, TSR 042, pemetrexed, and cisplatin in Part 1g).
• During the initial 21 days (for patients receiving one dose each of TSR 022, TSR 042, pemetrexed, and carboplatin in Part 1h).
• Incidence of TEAEs during the DLT observation period (i.e., days 1–28 for Part 1a, days 1–42 for Parts 1b, 1c, and 1d, and days 1–21 for Parts 1f, 1g, and 1h).
• Incidence of TEAEs, serious adverse events (SAEs), irAEs, TEAEs leading to death, and AEs leading to discontinuation of treatment within a maximum of 90 days after the last dose of the investigational drug during treatment.
• Clinical laboratory parameters (hematology, chemistry, thyroid function, urinalysis), vital signs, ECOG performance status, electrocardiogram (ECG) parameters, physical examination, and use of concomitant medications.
Efficacy:
• Primary endpoint (antitumor activity in Parts 1e and 2): ORR, defined as the proportion of patients achieving a complete response (CR) or partial response (PR) as assessed by the trial administrator according to RECIST version 1.1.
PK/Pharmacodynamics:
• PK endpoints include serum concentrations of TSR 022, TSR 042, and TSR 033, and derived PK parameters (Parts 1a, 1b, 1c, 1d, and the Hong Kong/Taiwan subgroup in Part 2F), such as AUC, minimum concentration (Cmin), and terminal half-life (t1/2) (if data permit).
• Serum concentrations of TSR 022, TSR 042, and TSR 033 will be statistically aggregated. • PK analysis in Parts 1a through 1d, and in Part 2F for the Hong Kong/Taiwan subgroup, may include assessment of AUC (time 0 to the last evaluated AUC [AUC0-last], time 0 to infinity [AUC0∞], and AUC during the dosing interval [AUCtau]), Cmin, maximum concentration (Cmax), time to reach Cmax (tmax), clearance (CL), volume of distribution (V), and t1/2 (if data permits).
• Immunogenicity: Serum samples used for analysis of anti-TSR-022 antibody (all groups), TSR-042, and/or TSR-033 antibody in Parts 1c, 1d, 1e, 1f, 1g, 1h, and the following Part 2 concomitant treatment groups: A2 (melanoma), B2 (NSCLC), C2 (CRC), and D (NSCLC screened by TIM-3).
• Pharmacodynamics: In vitro analysis of TIM-3 and/or LAG-3 receptor occupancy rates on circulating blood cells.
Biomarkers:
• Blood biomarkers may include serum cytokines, circulating immune cells, circulating tumor DNA (ctDNA), and circulating tumor cells.
• DLT
• Within the first 28 days (for patients receiving 2 doses of TSR 022 in Part 1a [i.e., days 1 and 15]), and
• Within the first 42 days (for patients receiving 3 doses of TSR 022 in Part 1b, and 3 doses of nivolumab in Part 1b [i.e., days 1, 15, and 29 of the first 42 days of treatment]), and
• Within the first 42 days (for patients receiving 2 doses each of TSR-022 and TSR-042 in Part 1c [i.e., days 1 and 21 of the first 42 days of treatment in Part 1])
• Within the first 42 days (for patients receiving 2 doses each of TSR-022, TSR-042, and TSR-033 in Part 1d [i.e., days 1 and 29 of the first 42 days of treatment]) [Part 1: Days 1 and 21 of the initial 42-day treatment period]
• During the initial 21 days (for patients receiving one dose each of TSR 022, TSR-042, and docetaxel in Part 1f).
• During the initial 21 days (for patients receiving one dose each of TSR 022, TSR 042, pemetrexed, and cisplatin in Part 1g).
• During the initial 21 days (for patients receiving one dose each of TSR 022, TSR 042, pemetrexed, and carboplatin in Part 1h).
• Incidence of TEAEs during the DLT observation period (i.e., days 1–28 for Part 1a, days 1–42 for Parts 1b, 1c, and 1d, and days 1–21 for Parts 1f, 1g, and 1h).
• Incidence of TEAEs, serious adverse events (SAEs), irAEs, TEAEs leading to death, and AEs leading to discontinuation of treatment within a maximum of 90 days after the last dose of the investigational drug during treatment.
• Clinical laboratory parameters (hematology, chemistry, thyroid function, urinalysis), vital signs, ECOG performance status, electrocardiogram (ECG) parameters, physical examination, and use of concomitant medications.
Efficacy:
• Primary endpoint (antitumor activity in Parts 1e and 2): ORR, defined as the proportion of patients achieving a complete response (CR) or partial response (PR) as assessed by the trial administrator according to RECIST version 1.1.
PK/Pharmacodynamics:
• PK endpoints include serum concentrations of TSR 022, TSR 042, and TSR 033, and derived PK parameters (Parts 1a, 1b, 1c, 1d, and the Hong Kong/Taiwan subgroup in Part 2F), such as AUC, minimum concentration (Cmin), and terminal half-life (t1/2) (if data permit).
• Serum concentrations of TSR 022, TSR 042, and TSR 033 will be statistically aggregated. • PK analysis in Parts 1a through 1d, and in Part 2F for the Hong Kong/Taiwan subgroup, may include assessment of AUC (time 0 to the last evaluated AUC [AUC0-last], time 0 to infinity [AUC0∞], and AUC during the dosing interval [AUCtau]), Cmin, maximum concentration (Cmax), time to reach Cmax (tmax), clearance (CL), volume of distribution (V), and t1/2 (if data permits).
• Immunogenicity: Serum samples used for analysis of anti-TSR-022 antibody (all groups), TSR-042, and/or TSR-033 antibody in Parts 1c, 1d, 1e, 1f, 1g, 1h, and the following Part 2 concomitant treatment groups: A2 (melanoma), B2 (NSCLC), C2 (CRC), and D (NSCLC screened by TIM-3).
• Pharmacodynamics: In vitro analysis of TIM-3 and/or LAG-3 receptor occupancy rates on circulating blood cells.
Biomarkers:
• Blood biomarkers may include serum cytokines, circulating immune cells, circulating tumor DNA (ctDNA), and circulating tumor cells.
Inclution Criteria
Inclusion Criteria
Participant is at least 18 years of age.
Female participants of childbearing potential must have a negative serum or urine pregnancy test within 72 hours prior to the date of the first dose of study medication or be of non-childbearing potential.
Participant has an ECOG performance status of less than or equal to (<=)1.
Participant has adequate organ function.
Inclusion Criteria for Participants in Part 1 and Part 2 Cohorts A, B, and C:
Participant with advanced or metastatic solid tumor who meets the requirements for the part of the study/cohort he/she will participate in, as follows:
Part 2: Histologically proven advanced (unresectable) or metastatic solid tumor that is measurable by computed tomography (CT) or magnetic resonance imaging (MRI) per RECIST version 1.1 criteria Inclusion Criteria for Participants in Part 2 Cohort D
Participants with advanced or metastatic non-small cell lung carcinoma (NSCLC) that is measurable by CT or MRI per RECIST version 1.1 criteria and meet the following criteria:
NSCLC histology includes squamous or non-squamous cell carcinoma.
Participants have received no more than 2 prior lines of therapy, which must include a platinum-based chemotherapy (for example [e.g.], cisplatin, carboplatin) and an anti- programmed death-ligand 1 (PD-L1) antibody.
Participants must have documented radiographic progression by RECIST version 1.1 criteria on prior anti-programmed cell death protein (PD-1) or anti-PD-L1 therapy.
Biopsies -All participants enrolled must undergo a biopsy prior to study entry, and the biopsy tissue must be submitted to the central laboratory for all participants in order to determine T-cell immunoglobulin and mucin-domain containing-3 (TIM-3) expression level prior to first dose. If a participant has had a biopsy prior to entering the 35-day screening period and within approximately 12 weeks of study treatment, that biopsy may be accepted as the Baseline fresh biopsy.
Inclusion Criteria for Participants in Part 2 Cohort E
Participant is greater than or equal to (>=)18 years old, is able to understand the study procedures, and agrees to participate in the study by providing written informed consent which includes compliance with the requirements and restrictions listed in the Informed consent form (ICF) and protocol.
Participant has histologically or cytologically proven advanced or metastatic NSCLC, and only squamous or non-squamous cell carcinoma.
Participant has received no more than 2 prior lines of therapy for advanced or metastatic disease, which must only include a platinum-based (eg, cisplatin, carboplatin) doublet chemotherapy regimen and an anti-PD-1 or anti-PD-L1 antibody (no other biologic agents alone or in combination; novel combinations are not allowed). Participants previously treated with targeted therapies, including angiogenesis inhibitors (eg, bevacizumab, ramucirumab, lenvatinib), are not eligible.
Participant has measurable disease, that is, presenting with at least 1 measurable lesion per RECIST v1.1 as determined by the local site Investigator/radiology assessment. Target lesions situated in a previously irradiated area are considered measurable if disease progression has been demonstrated in such lesions and if there are other target lesions. If there is only 1 target lesion that was previously irradiated, the participant is not eligible.
Participant has documented radiological disease progression on prior platinum-based chemotherapy and on prior anti-PD-1 or anti-PD-L1 therapy according to RECIST v1.1.
Participant agrees to submit an archival formalin fixed paraffin embedded (FFPE) tumor tissue specimen that was collected on or after diagnosis of metastatic disease from location(s) not irradiated prior to biopsy. Both tissue block and freshly cut slides are acceptable. If archival tissue is not available, the participant must undergo biopsy prior to study entry.
Participant has an ECOG performance status score of 0 or 1.
Participant has a life expectancy of at least 3 months and is anticipated to be able to complete 4 cycles of docetaxel treatment.
Participant has adequate organ function as defined in the protocol
Contraceptive use by male and female participants should be consistent with local regulations regarding the methods of contraception for those participating in clinical studies.
Inclusion Criteria for Participants in Part 2 Cohort F
Histologically confirmed locally advanced or metastatic and/or unresectable Hepatocellcular Carcinoma (HCC)
Barcelona Clinic Liver Cancer Stage B or C
Cirrhosis grade of Child-Pugh Class A
No prior systemic therapy for HCC
Documented HBV testing at screening, including hepatitis B surface antigen (HBsAg), hepatitis B surface antibody (HBsAB) and hepatitis B core antibody (HBcAb). Participants with a positive HBsAg will require negative hepatitis B virus (HBV) DNA testing at screening.
Participants with chronic HBV infection (HBsAg +) are required to be receiving effective antiviral therapy (i.e., with Tenofovir or Entecavir) for at least 14 days with willingness to continue for the length of the study and have HBV deoxyribonucleic acid (DNA) less than 100 International Units Per Milliliter (IU/mL) within 28 days prior to initiation of study treatment.
Participants with chronic HBV infection (HBsAg+) require documented Hepatitis D virus (HDV) antibody testing conducted at screening. If HDV antibody is positive, then HDV ribonucleic acid (RNA) must be negative to participate.
Participants with a negative HBsAg and positive HBcAb result are eligible only if HBV DNA is negative (Past HBV participants).
Documented hepatitis C virus (HCV) antibody testing conducted at screening. If HCV antibody is positive, then HCV RNA must be negative. Participants with recently treated HCV prior to study start must be greater than (>)12 weeks from final HCV treatment.
Must have measurable disease, defined as at least one tumor lesion that can be accurately measured according to RECIST v1.1
Participant agrees to submit an archival FFPE tumor tissue specimen that was collected on or after diagnosis of metastatic disease from location(s) not irradiated prior to biopsy. Both tissue block and freshly cut slides are acceptable. If archival tissue is not available, the participant must undergo biopsy prior to study entry.
• Participants are also encouraged, but not required, to have a fresh tumor tissue biopsy of a primary or metastatic tumor prior to dosing (samples will be used to enable biomarker analysis).
International normalized ratio (INR) or prothrombin time (PT) <= 2× upper limit of normal (ULN) unless participant is receiving anticoagulant therapy as long as PT or partial thromboplastin (PTT) is within therapeutic range of intended use of anticoagulants. Activated partial thromboplastin time (aPTT) <=2×ULN unless participant is receiving anticoagulant therapy as long as PT or PTT is within therapeutic range of intended use of anticoagulants
Negative human immunodeficiency virus (HIV) test at screening The Investigator is responsible for review of medical history, menstrual history, and recent sexual activity to decrease the risk for inclusion of a woman with an early undetected pregnancy.
Participant is at least 18 years of age.
Female participants of childbearing potential must have a negative serum or urine pregnancy test within 72 hours prior to the date of the first dose of study medication or be of non-childbearing potential.
Participant has an ECOG performance status of less than or equal to (<=)1.
Participant has adequate organ function.
Inclusion Criteria for Participants in Part 1 and Part 2 Cohorts A, B, and C:
Participant with advanced or metastatic solid tumor who meets the requirements for the part of the study/cohort he/she will participate in, as follows:
Part 2: Histologically proven advanced (unresectable) or metastatic solid tumor that is measurable by computed tomography (CT) or magnetic resonance imaging (MRI) per RECIST version 1.1 criteria Inclusion Criteria for Participants in Part 2 Cohort D
Participants with advanced or metastatic non-small cell lung carcinoma (NSCLC) that is measurable by CT or MRI per RECIST version 1.1 criteria and meet the following criteria:
NSCLC histology includes squamous or non-squamous cell carcinoma.
Participants have received no more than 2 prior lines of therapy, which must include a platinum-based chemotherapy (for example [e.g.], cisplatin, carboplatin) and an anti- programmed death-ligand 1 (PD-L1) antibody.
Participants must have documented radiographic progression by RECIST version 1.1 criteria on prior anti-programmed cell death protein (PD-1) or anti-PD-L1 therapy.
Biopsies -All participants enrolled must undergo a biopsy prior to study entry, and the biopsy tissue must be submitted to the central laboratory for all participants in order to determine T-cell immunoglobulin and mucin-domain containing-3 (TIM-3) expression level prior to first dose. If a participant has had a biopsy prior to entering the 35-day screening period and within approximately 12 weeks of study treatment, that biopsy may be accepted as the Baseline fresh biopsy.
Inclusion Criteria for Participants in Part 2 Cohort E
Participant is greater than or equal to (>=)18 years old, is able to understand the study procedures, and agrees to participate in the study by providing written informed consent which includes compliance with the requirements and restrictions listed in the Informed consent form (ICF) and protocol.
Participant has histologically or cytologically proven advanced or metastatic NSCLC, and only squamous or non-squamous cell carcinoma.
Participant has received no more than 2 prior lines of therapy for advanced or metastatic disease, which must only include a platinum-based (eg, cisplatin, carboplatin) doublet chemotherapy regimen and an anti-PD-1 or anti-PD-L1 antibody (no other biologic agents alone or in combination; novel combinations are not allowed). Participants previously treated with targeted therapies, including angiogenesis inhibitors (eg, bevacizumab, ramucirumab, lenvatinib), are not eligible.
Participant has measurable disease, that is, presenting with at least 1 measurable lesion per RECIST v1.1 as determined by the local site Investigator/radiology assessment. Target lesions situated in a previously irradiated area are considered measurable if disease progression has been demonstrated in such lesions and if there are other target lesions. If there is only 1 target lesion that was previously irradiated, the participant is not eligible.
Participant has documented radiological disease progression on prior platinum-based chemotherapy and on prior anti-PD-1 or anti-PD-L1 therapy according to RECIST v1.1.
Participant agrees to submit an archival formalin fixed paraffin embedded (FFPE) tumor tissue specimen that was collected on or after diagnosis of metastatic disease from location(s) not irradiated prior to biopsy. Both tissue block and freshly cut slides are acceptable. If archival tissue is not available, the participant must undergo biopsy prior to study entry.
Participant has an ECOG performance status score of 0 or 1.
Participant has a life expectancy of at least 3 months and is anticipated to be able to complete 4 cycles of docetaxel treatment.
Participant has adequate organ function as defined in the protocol
Contraceptive use by male and female participants should be consistent with local regulations regarding the methods of contraception for those participating in clinical studies.
Inclusion Criteria for Participants in Part 2 Cohort F
Histologically confirmed locally advanced or metastatic and/or unresectable Hepatocellcular Carcinoma (HCC)
Barcelona Clinic Liver Cancer Stage B or C
Cirrhosis grade of Child-Pugh Class A
No prior systemic therapy for HCC
Documented HBV testing at screening, including hepatitis B surface antigen (HBsAg), hepatitis B surface antibody (HBsAB) and hepatitis B core antibody (HBcAb). Participants with a positive HBsAg will require negative hepatitis B virus (HBV) DNA testing at screening.
Participants with chronic HBV infection (HBsAg +) are required to be receiving effective antiviral therapy (i.e., with Tenofovir or Entecavir) for at least 14 days with willingness to continue for the length of the study and have HBV deoxyribonucleic acid (DNA) less than 100 International Units Per Milliliter (IU/mL) within 28 days prior to initiation of study treatment.
Participants with chronic HBV infection (HBsAg+) require documented Hepatitis D virus (HDV) antibody testing conducted at screening. If HDV antibody is positive, then HDV ribonucleic acid (RNA) must be negative to participate.
Participants with a negative HBsAg and positive HBcAb result are eligible only if HBV DNA is negative (Past HBV participants).
Documented hepatitis C virus (HCV) antibody testing conducted at screening. If HCV antibody is positive, then HCV RNA must be negative. Participants with recently treated HCV prior to study start must be greater than (>)12 weeks from final HCV treatment.
Must have measurable disease, defined as at least one tumor lesion that can be accurately measured according to RECIST v1.1
Participant agrees to submit an archival FFPE tumor tissue specimen that was collected on or after diagnosis of metastatic disease from location(s) not irradiated prior to biopsy. Both tissue block and freshly cut slides are acceptable. If archival tissue is not available, the participant must undergo biopsy prior to study entry.
• Participants are also encouraged, but not required, to have a fresh tumor tissue biopsy of a primary or metastatic tumor prior to dosing (samples will be used to enable biomarker analysis).
International normalized ratio (INR) or prothrombin time (PT) <= 2× upper limit of normal (ULN) unless participant is receiving anticoagulant therapy as long as PT or partial thromboplastin (PTT) is within therapeutic range of intended use of anticoagulants. Activated partial thromboplastin time (aPTT) <=2×ULN unless participant is receiving anticoagulant therapy as long as PT or PTT is within therapeutic range of intended use of anticoagulants
Negative human immunodeficiency virus (HIV) test at screening The Investigator is responsible for review of medical history, menstrual history, and recent sexual activity to decrease the risk for inclusion of a woman with an early undetected pregnancy.
Exclusion Criteria
Exclusion criteria:
History of Grade greater than or equal to (>=)3 immune-related AE with prior immunotherapy, with the exception of non-clinically significant lab abnormalities.
Participant has known uncontrolled central nervous system (CNS) metastases and/or carcinomatous meningitis.
Participant has a known additional malignancy that progressed or required active treatment within the last 2 years. Participants with a prior or concurrent malignancy whose natural history or treatment does not have the potential to interfere with the safety or efficacy assessment of the investigational regimen may be included only after discussion with the Medical Monitor.
Participant is considered a poor medical risk due to a serious, uncontrolled medical disorder, non-malignant systemic disease or active infection requiring systemic therapy.
Participant is pregnant or breastfeeding or expecting to conceive children within the projected duration of the study, starting with the Screening Visit through 150 days after the last dose of study treatment.
Participant has a diagnosis of immunodeficiency or is receiving systemic steroid therapy or any other form of immunosuppressive therapy within 7 days prior to the first dose of study treatment.
Exclusion Criteria for Participants in Part 2 Cohort D
A participant with negative (as determined by Central Testing Lab) or unevaluable TIM-3 expression from tissue obtained prior to study entry will not be eligible for the study.
Participant has received prior therapy as defined below:
Prior treatment with anti-PD-1, anti-PD-L1, or anti-PD-L2 agent that resulted in permanent discontinuation due to an AE.
Prior treatment with an anti-lymphocyte activation gene (LAG)-3 or anti-TIM-3.
Radiologic or clinical progression <= 8 weeks after initiation of prior anti-PD-1 or anti-PD-L1 antibody.
Participants with known epidermal growth factor receptor (EGFR) mutation, anaplastic lymphoma kinase (ALK) translocation, or receptor tyrosine kinase (ROS1) mutation.
Participant has received a vaccine other than a vaccine against severe acute respiratory syndrome (SARS)-coronavirus 2 (CoV-2) infection ("Coronavirus Disease 2019" [COVID-19]) within 7 days of planned start of study therapy. The use of all COVID-19 vaccines is allowed, with the exception of COVID-19 vaccines using the recombinant adenoviral vector platform within 30 days of planned start of study therapy. If a COVID-19 vaccine using this platform is to be administered within 30 days of planned start of study therapy, this must first be discussed with and approved by the Sponsor's Medical Monitor.
Exclusion Criteria for Participants in Part 2 Cohort E
Participant has been previously treated with an anti PD 1, anti PD L1, or anti PD L2 agent that resulted in permanent discontinuation due to an AE
Participant has been previously treated with an anti TIM-3 or anti cytotoxic T lymphocyte-associated protein 4 (CTLA 4) agent or docetaxel.
Participant has a documented sensitizing EGFR, ALK, or ROS-1 mutation. Participants whose tumors have not been tested for these driver mutations and therefore who have unknown driver mutation status are not eligible. Participants with squamous histology do not need to be tested for these driver mutations.
Participant had radiological or clinical disease progression (that is [ie,] worsening performance status, clinical symptoms, and laboratory data) <=8 weeks after initiation of prior anti PD 1 or anti-PD-L1 antibody. The clinical disease progression should have been confirmed by a subsequent radiological scan.
Participant has received radiation to the lung that is >30 Gray (Gy) within 6 months prior to the first dose of study treatment.
Participant has completed palliative radiotherapy within 7 days prior to the first dose of study treatment.
Participant has an additional malignancy or a history of prior malignancy, with the exception of adequately treated basal or squamous skin cancer, cervical carcinoma in situ, or bladder carcinoma in situ without evidence of disease, or had a malignancy treated with curative intent and with no evidence of disease recurrence for 5 years since the initiation of that therapy.
Participant has known new or progressive brain metastases and/or leptomeningeal metastases. Participants who have received prior therapy for their brain metastases and have radiologically stable central nervous system disease may participate, provided they are neurologically stable for at least 4 weeks before study entry and are off corticosteroids within 3 days prior to the first dose of study treatment.
Participant has tested positive for the following at Screening or within 3 months before the first dose of study treatment:
Presence of hepatitis B surface antigen.
Presence of hepatitis C antibody in the absence of an Ribonucleic acid (RNA) test for hepatitis C virus.
Participant has known human immunodeficiency virus (HIV) (positive for HIV 1 or HIV 2 antibodies).
Participant has active autoimmune disease that required systemic treatment in the past 2 years, is immunocompromised in the opinion of the Investigator, or is receiving systemic immunosuppressive treatment. Replacement therapy (eg, thyroxine, insulin, or physiologic corticosteroid replacement therapy of prednisone, or equivalent, for adrenal or pituitary insufficiency) is not considered a form of systemic treatment.
Participant has received systemic steroid therapy within 3 days prior to the first dose of the study treatment or is receiving any other form of immunosuppressive medication. Replacement therapy is not considered a form of systemic therapy. Use of inhaled corticosteroids, local steroid injection, or steroid eye drops is allowed.
Participant has current interstitial lung disease, current pneumonitis, or a history of pneumonitis that required the use of glucocorticoids to assist with management. Lymphangitic spread of the NSCLC is not exclusionary.
Participant does not meet requirements per local prescribing guidelines for receiving treatment with docetaxel, including severe hypersensitivity reactions to drugs formulated with polysorbate 80.
Participant has received prior anticancer therapy (chemotherapy, targeted therapies, radiotherapy, or immunotherapy) within 21 days, or less than 5 times the half life of the most recent therapy prior to study Day 1, whichever is shorter.
Exclusion Criteria for Participants in Part 2 Cohort F
Known fibrolamellar HCC, sarcomatoid HCC or mixed cholangiocarcinoma and HCC
Participant must not have had major surgery <= 3 weeks prior to initiating protocol therapy and participant must have recovered from any surgical effects
Participants must not have received investigational therapy <= 4 weeks, or within a time interval less than at least 5 half-lives of the investigational agent, whichever is shorter, prior to initiating protocol therapy.
Active or untreated central nervous system (CNS) and leptomeningeal metastases
Prior therapy with any medication targeting PD-1, PD-L1, or TIM-3
Participant must not have a known hypersensitivity to TSR-042 and TSR-022 components or excipients.
Participants with active malignancy (other than HCC) or a prior malignancy within the past 2 years are excluded. Participants with completely resected cutaneous melanoma (early stage), basal cell carcinoma, cutaneous squamous cell carcinoma, cervical carcinoma in-situ, breast carcinoma in-situ, and localized prostate cancer are eligible
Participant must not have serious, uncontrolled medical disorder, or nonmalignant systemic disease as determined by the treating physician. Examples include, but are not limited to uncontrolled ventricular arrhythmia, uncontrolled major seizure disorder, unstable spinal cord compression, or superior vena cava syndrome.
Has a history or evidence of cardiac abnormalities within the 6 months prior to enrollment, including:
Serious, uncontrolled cardiac arrhythmia or clinically significant ECG abnormalities including second-degree (Type II) or third-degree atrioventricular (AV) block.
Cardiomyopathy, myocarditis, myocardial infarction, acute coronary syndromes (including angina pectoris), coronary angioplasty, stenting, or bypass grafting.
Congestive heart failure [New York Heart Association (NYHA) Class III or IV]
Symptomatic pericarditis
Known history of HIV infection
Active tuberculosis infection or other microbial infection or any active systemic infection requiring parenteral antibiotic therapy. All prior infections must have resolved following optimal therapy.
Participant has an active autoimmune disease that has required systemic treatment in the past 2 years (. i.e., with use of disease-modifying agents, corticosteroids, or immunosuppressive drugs). Replacement therapy (e.g., thyroxine, insulin, or physiologic corticosteroid replacement therapy for adrenal or pituitary insufficiency, etc.) is not considered a form of systemic treatment.
History of idiopathic pulmonary fibrosis, interstitial lung disease, bronchial asthma, organizing pneumonia, bronchiolitis obliterans, drug-induced pneumonitis, or idiopathic pneumonitis
History of organ transplantation including allogeneic bone marrow transplantation
Participant has a diagnosis of immunodeficiency or has been receiving systemic steroid therapy or any other form of immunosuppressive therapy within 7 days prior to initiating protocol therapy.
Participant has received a live vaccine within 7 days of initiating protocol therapy. Seasonal flu vaccines that do not contain live virus and COVID 19 vaccines are permitted.
Psychiatric illness/social situations that would limit compliance with study requirements
Pregnant, lactating, breastfeeding, or intending to become pregnant during the study and for 150 days after the study
History of Grade greater than or equal to (>=)3 immune-related AE with prior immunotherapy, with the exception of non-clinically significant lab abnormalities.
Participant has known uncontrolled central nervous system (CNS) metastases and/or carcinomatous meningitis.
Participant has a known additional malignancy that progressed or required active treatment within the last 2 years. Participants with a prior or concurrent malignancy whose natural history or treatment does not have the potential to interfere with the safety or efficacy assessment of the investigational regimen may be included only after discussion with the Medical Monitor.
Participant is considered a poor medical risk due to a serious, uncontrolled medical disorder, non-malignant systemic disease or active infection requiring systemic therapy.
Participant is pregnant or breastfeeding or expecting to conceive children within the projected duration of the study, starting with the Screening Visit through 150 days after the last dose of study treatment.
Participant has a diagnosis of immunodeficiency or is receiving systemic steroid therapy or any other form of immunosuppressive therapy within 7 days prior to the first dose of study treatment.
Exclusion Criteria for Participants in Part 2 Cohort D
A participant with negative (as determined by Central Testing Lab) or unevaluable TIM-3 expression from tissue obtained prior to study entry will not be eligible for the study.
Participant has received prior therapy as defined below:
Prior treatment with anti-PD-1, anti-PD-L1, or anti-PD-L2 agent that resulted in permanent discontinuation due to an AE.
Prior treatment with an anti-lymphocyte activation gene (LAG)-3 or anti-TIM-3.
Radiologic or clinical progression <= 8 weeks after initiation of prior anti-PD-1 or anti-PD-L1 antibody.
Participants with known epidermal growth factor receptor (EGFR) mutation, anaplastic lymphoma kinase (ALK) translocation, or receptor tyrosine kinase (ROS1) mutation.
Participant has received a vaccine other than a vaccine against severe acute respiratory syndrome (SARS)-coronavirus 2 (CoV-2) infection ("Coronavirus Disease 2019" [COVID-19]) within 7 days of planned start of study therapy. The use of all COVID-19 vaccines is allowed, with the exception of COVID-19 vaccines using the recombinant adenoviral vector platform within 30 days of planned start of study therapy. If a COVID-19 vaccine using this platform is to be administered within 30 days of planned start of study therapy, this must first be discussed with and approved by the Sponsor's Medical Monitor.
Exclusion Criteria for Participants in Part 2 Cohort E
Participant has been previously treated with an anti PD 1, anti PD L1, or anti PD L2 agent that resulted in permanent discontinuation due to an AE
Participant has been previously treated with an anti TIM-3 or anti cytotoxic T lymphocyte-associated protein 4 (CTLA 4) agent or docetaxel.
Participant has a documented sensitizing EGFR, ALK, or ROS-1 mutation. Participants whose tumors have not been tested for these driver mutations and therefore who have unknown driver mutation status are not eligible. Participants with squamous histology do not need to be tested for these driver mutations.
Participant had radiological or clinical disease progression (that is [ie,] worsening performance status, clinical symptoms, and laboratory data) <=8 weeks after initiation of prior anti PD 1 or anti-PD-L1 antibody. The clinical disease progression should have been confirmed by a subsequent radiological scan.
Participant has received radiation to the lung that is >30 Gray (Gy) within 6 months prior to the first dose of study treatment.
Participant has completed palliative radiotherapy within 7 days prior to the first dose of study treatment.
Participant has an additional malignancy or a history of prior malignancy, with the exception of adequately treated basal or squamous skin cancer, cervical carcinoma in situ, or bladder carcinoma in situ without evidence of disease, or had a malignancy treated with curative intent and with no evidence of disease recurrence for 5 years since the initiation of that therapy.
Participant has known new or progressive brain metastases and/or leptomeningeal metastases. Participants who have received prior therapy for their brain metastases and have radiologically stable central nervous system disease may participate, provided they are neurologically stable for at least 4 weeks before study entry and are off corticosteroids within 3 days prior to the first dose of study treatment.
Participant has tested positive for the following at Screening or within 3 months before the first dose of study treatment:
Presence of hepatitis B surface antigen.
Presence of hepatitis C antibody in the absence of an Ribonucleic acid (RNA) test for hepatitis C virus.
Participant has known human immunodeficiency virus (HIV) (positive for HIV 1 or HIV 2 antibodies).
Participant has active autoimmune disease that required systemic treatment in the past 2 years, is immunocompromised in the opinion of the Investigator, or is receiving systemic immunosuppressive treatment. Replacement therapy (eg, thyroxine, insulin, or physiologic corticosteroid replacement therapy of prednisone, or equivalent, for adrenal or pituitary insufficiency) is not considered a form of systemic treatment.
Participant has received systemic steroid therapy within 3 days prior to the first dose of the study treatment or is receiving any other form of immunosuppressive medication. Replacement therapy is not considered a form of systemic therapy. Use of inhaled corticosteroids, local steroid injection, or steroid eye drops is allowed.
Participant has current interstitial lung disease, current pneumonitis, or a history of pneumonitis that required the use of glucocorticoids to assist with management. Lymphangitic spread of the NSCLC is not exclusionary.
Participant does not meet requirements per local prescribing guidelines for receiving treatment with docetaxel, including severe hypersensitivity reactions to drugs formulated with polysorbate 80.
Participant has received prior anticancer therapy (chemotherapy, targeted therapies, radiotherapy, or immunotherapy) within 21 days, or less than 5 times the half life of the most recent therapy prior to study Day 1, whichever is shorter.
Exclusion Criteria for Participants in Part 2 Cohort F
Known fibrolamellar HCC, sarcomatoid HCC or mixed cholangiocarcinoma and HCC
Participant must not have had major surgery <= 3 weeks prior to initiating protocol therapy and participant must have recovered from any surgical effects
Participants must not have received investigational therapy <= 4 weeks, or within a time interval less than at least 5 half-lives of the investigational agent, whichever is shorter, prior to initiating protocol therapy.
Active or untreated central nervous system (CNS) and leptomeningeal metastases
Prior therapy with any medication targeting PD-1, PD-L1, or TIM-3
Participant must not have a known hypersensitivity to TSR-042 and TSR-022 components or excipients.
Participants with active malignancy (other than HCC) or a prior malignancy within the past 2 years are excluded. Participants with completely resected cutaneous melanoma (early stage), basal cell carcinoma, cutaneous squamous cell carcinoma, cervical carcinoma in-situ, breast carcinoma in-situ, and localized prostate cancer are eligible
Participant must not have serious, uncontrolled medical disorder, or nonmalignant systemic disease as determined by the treating physician. Examples include, but are not limited to uncontrolled ventricular arrhythmia, uncontrolled major seizure disorder, unstable spinal cord compression, or superior vena cava syndrome.
Has a history or evidence of cardiac abnormalities within the 6 months prior to enrollment, including:
Serious, uncontrolled cardiac arrhythmia or clinically significant ECG abnormalities including second-degree (Type II) or third-degree atrioventricular (AV) block.
Cardiomyopathy, myocarditis, myocardial infarction, acute coronary syndromes (including angina pectoris), coronary angioplasty, stenting, or bypass grafting.
Congestive heart failure [New York Heart Association (NYHA) Class III or IV]
Symptomatic pericarditis
Known history of HIV infection
Active tuberculosis infection or other microbial infection or any active systemic infection requiring parenteral antibiotic therapy. All prior infections must have resolved following optimal therapy.
Participant has an active autoimmune disease that has required systemic treatment in the past 2 years (. i.e., with use of disease-modifying agents, corticosteroids, or immunosuppressive drugs). Replacement therapy (e.g., thyroxine, insulin, or physiologic corticosteroid replacement therapy for adrenal or pituitary insufficiency, etc.) is not considered a form of systemic treatment.
History of idiopathic pulmonary fibrosis, interstitial lung disease, bronchial asthma, organizing pneumonia, bronchiolitis obliterans, drug-induced pneumonitis, or idiopathic pneumonitis
History of organ transplantation including allogeneic bone marrow transplantation
Participant has a diagnosis of immunodeficiency or has been receiving systemic steroid therapy or any other form of immunosuppressive therapy within 7 days prior to initiating protocol therapy.
Participant has received a live vaccine within 7 days of initiating protocol therapy. Seasonal flu vaccines that do not contain live virus and COVID 19 vaccines are permitted.
Psychiatric illness/social situations that would limit compliance with study requirements
Pregnant, lactating, breastfeeding, or intending to become pregnant during the study and for 150 days after the study
The Estimated Number of Participants
-
Taiwan
9 participants
-
Global
1221 participants
